A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

  • STATUS
    Recruiting
  • End date
    Aug 4, 2025
  • participants needed
    146
  • sponsor
    Incyte Corporation
Updated on 29 October 2022
metastatic melanoma
cancer
combinations
BRAF
immunomodulators
braf v600 mutation
pd-1 inhibitor
immunologic adjuvant

Summary

The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.

Details
Condition Melanoma
Treatment INCAGN02385, INCAGN02390, INCMGA00012.
Clinical Study IdentifierNCT04370704
SponsorIncyte Corporation
Last Modified on29 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Phase 1 Parts 1-4): Participants with locally advanced or metastatic solid tumors (locally advanced disease must not be amenable to resection with curative intent) that have failed available therapies, including anti-PD-(L)1 therapy if applicable, that are known to confer clinical benefit, or who are intolerant to, or ineligible for standard treatment. Prior anti-PD-(L)1 therapy should not have been discontinued because of intolerance
Phase 2, Cohort A
Participant with histologically confirmed unresectable/metastatic melanoma, whose disease failed prior anti-PD-(L)1 therapy (alone or as part of a combination) and meeting one of the following criteria
Participant who failed prior adjuvant anti-PD-(L)1 therapy for resectable melanoma must have received prior anti-PD-(L)1 for ≥ 6 weeks and experienced disease progression while still on active adjuvant therapy containing anti-PD-(L)1, or participant who had early relapse occurring < 24 weeks after end of adjuvant anti-PD-(L)1 therapy. Progressive disease must be ascertained by confirmatory biopsy collected at baseline
Participant whose unresectable/metastatic disease progressed while on or within < 24 weeks of completion of anti-PD-(L)1 for inresectable/metastatic melanoma. Progressive disease must have been confirmed by imaging ≥ 4 weeks after evidence of initial disease progression
Participant must have received no more than 2 prior lines of therapy for melanoma
and at least one prior regimen must have contained anti-PD-(L)1 therapy (alone
or as part of a combination) either in the adjuvant and/or advanced/metastatic
setting
Participants must have had known BRAF V600 mutation status per local institutional testing standards
Participants must have fresh biopsy available after completing prior PD-(L)1 therapy or be willing and able to safely undergo pretreatment tumor biopsies (core or excisional). Determination of whether participants can safely undergo biopsy should be made by the treating physician in consultation with the individual performing the biopsy
Participant must have at least 1 measurable tumor lesion per RECIST v1.1
Phase 2, Cohort B
ECOG performance status 0 or 1
Participant with previously untreated, histologically confirmed Stage III (unresectable) or IV melanoma per the American Joint Committee on Cancer v8 staging system
Willingness to avoid pregnancy or fathering children
Participants must not have had prior systemic anticancer therapy for unresectable or metastatic melanoma
Participants must have had known BRAF V600 mutation status per local institutional testing standards
Participants must have fresh biopsy available or be willing and able to safely undergo pretreatment tumor biopsies (core or excisional). Determination of whether participants can safely undergo biopsy should be made by the treating physician in consultation with the individual performing the biopsy
Phase 2 (Cohorts A and B): Participant must have at least 1 measurable tumor lesion
per RECIST v1.1

Exclusion Criteria

Laboratory and medical history parameters outside the protocol-defined range
Known hypersensitivity or severe reaction to any component of the study drugs or formulation components ) within 14 days before study Day 1
Receipt of a live vaccine within 30 days of planned start of study treatment
Receipt of anticancer medications or investigational drugs within the following intervals before the first administration of study treatment
Participant who had prior treatment with a LAG-3 or TIM-3 targeted agent
Phase 1: (Parts 1-4)
Phase 2
≤28 days or 5 half-lives (whichever is longer) before the first dose for all other investigational agents or devices. For investigational agents with long half-lives (eg, > 5 days), enrollment before the fifth half-life requires medical monitor approval
Administration of colony-stimulating factors (including granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 14 days before study Day 1
Cohort A: Participant who has discontinued anti-PD-(L)1 therapy due to toxicity or other reasons unrelated to toxicity, then subsequently experienced disease progression
Cohort A: Participant who had experienced objective response (PR/CR) and had stopped anti-PD-(L)1 therapy due to maximal benefit
Cohort A: Participant with multiple metastases that achieved mixed tumor response to prior anti-PD-(L)1 therapy (such as isolated progressive lesion in a context of PR/CR or SD for other lesions) or achieved overall disease progression based only on a single new lesion
Cohort B: Participant who has or has had uveal melanoma
Receipt of anticancer therapy (immunotherapy, chemotherapy, targeted therapy or hormonal therapy) within 21 days of the first administration of study treatment, with the exception of localized radiotherapy
Palliative radiation therapy administered within 1 week of first dose of study treatment or radiation therapy in the thoracic region that is > 30 Gy within 6 months of the first dose of study treatment
If participant received major surgery, then they must have recovered adequately from toxicities and/or complications from the intervention before starting study treatment
Treatment-related toxicity related to prior therapy that has not recovered to ≤ Grade 1 (with the exception of alopecia and anemia not requiring transfusional support), unless approved by the medical monitor
History of immune-related toxicity during prior checkpoint inhibitor therapy for which permanent discontinuation of therapy is recommended (per product label or consensus guidelines), OR any immune-related toxicity requiring intensive or prolonged immunosuppression to manage (with the exception of endocrinopathy that is well controlled on stable dose of replacement hormones such as hypothyroidism or adrenal insufficiency, or Grade 3 rashes that resolved with topical therapy or asymptomatic lipase elevations that do not require treatment interruption or uveitis that resolved with steroid drops)
Has an active autoimmune disease requiring systemic immunosuppression with corticosteroids (> 10 mg/day of prednisone or equivalent) or immunosuppressive drugs within 14 days before the first dose of study treatment
Receiving chronic systemic corticosteroids (> 10 mg/day of prednisone or equivalent)
Active infections requiring systemic antibiotics, or antifungal or antiviral treatment within 7 days before first dose of study treatment
History of organ transplant, including allogeneic stem cell transplantation
Evidence of interstitial lung disease or active, noninfectious pneumonitis
Known active HBV or HCV infection or risk of reactivation of HBV or HCV
Participants who are known to be HIV-positive
Known active brain or CNS metastases including carcinomatous meningitis
Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry with the exception of cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy after treatment with curative intent
Participants with impaired cardiac function or clinically significant cardiac disease
History or presence of an abnormal ECG that, in the investigator's opinion, is clinically meaningful
Women who are pregnant or breastfeeding
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note